Physicians sort out pros and cons of several new IOLs on the market
Nov 12, 2021 · The 2 newest multifocal IOLs—AcrySof IQ PanOptix (Alcon) and Tecnis Synergy (Johnson + Johnson Vision)—almost guarantee a broader range of vision than EDoF IOLs but not the avoidance of photic phenomena, Sood said. The PanOptix is a trifocal lens with negative spherical aberration on its anterior surface that has diffractive rings in the ...
Ophthalmology Times - Ophthalmology news, articles, and events
November 6th 2024. In an interview with David Hutton of Ophthalmology Times, Ash Abbey, MD, discusses the Phase 3 LUGANO trial for EYP-1901 in treating wet age-related macular degeneration. Abbey discusses the trial’s non-inferiority objectives, treatment schedule, patient outcomes like reduced treatment burden, and anatomical stability.
Ophthalmologists: Castor oil shouldn’t be rubbed in the eyes, no …
Aug 8, 2023 · Ophthalmologists are issuing a warning not to use castor oil as a way to treat vision problems amid claims circulating on TikTok. In its heyday, castor oil was considered a jack-of-all-trades home remedy, used as a laxative, a moisturizer and even as a chest rub to ease lung congestion. Now, it is making a comeback as some influencers on TikTok ...
Dispelling myths about refractive lens exchange - Ophthalmology …
Sep 7, 2020 · Ninety-nine percent of the responders considered themselves refractive surgeons and 34% had undergone a laser vision correction themselves. Almost 50% of those who underwent laser vision correction were in their 30s, 30% in their 40s, and 22% in their 20s at the time of surgery. Of the survey responders, 8.5% reported having undergone a lens ...
Fluorometholone acetate: More benefit than meets the eye
Dec 11, 2019 · The ability of a drug to penetrate into the ocular tissues is key to controlling inflammation. “All fluorometholones are not the same,” said Beeran Meghpara, MD, and with good reason.Fluorometholone is the active steroid in formulations used to treat ocular inflammation- however, it is what doesn’t meet the eye that makes the difference, i.e., the vehicle.
About - Ophthalmology Times
About. Ophthalmology Times is a physician-driven media brand that presents cutting-edge advancements and analysis from around the world in surgery, clinical diagnosis, therapeutics, device technology, imaging, and gene therapy to elevate the delivery of progressive eye health from physician to patient. Ophthalmology Times’ vision is to be the ...
News - Ophthalmology Times
Veterans Administration ophthalmologist invents device to help with eye drops. October 29th 2024. Julie Schallhorn, MD, MS, also is an associate professor of ophthalmology at the University of California San Francisco, has drawn upon her bioengineering background to develop a device to simplify eye drop administration.
FDA approves pilocarpine hydrochloride ophthalmic solution for ...
Oct 18, 2023 · Orasis Pharmaceuticals announced the FDA has approved pilocarpine hydrochloride ophthalmic solution 0.4% (Qlosi) for the treatment of presbyopia in adults. The company announced it expects to have pilocarpine hydrochloride ophthalmic solution commercially available in the U.S. in the first half of 2024 …
Identifying, managing dysphotopsia after cataract surgery
Apr 25, 2014 · Boston — Following cataract surgery, patients can present with a variety of visual complaints-i.e., dysphotopsias, aberrant optical phenomena that interfere with vision after IOL implantation. Positive dysphotopsias include rainbows, streaks, crescents, rings, halos, and veiling glare, haze, and fog. Negative dysphotopsias are relative and ...
IOL Advances - Ophthalmology Times
David Hutton; OT Staff Reports. December 7th 2021. The company will begin commercialization of the IC-8 small aperture IOL, used for cataract patients, upon successful completion of the manufacturing facility inspections and receipt of an official approval order from the FDA, which the company estimates in Q2 2022.